Timing of onset, burden, and post-discharge mortality of persistent critical illness in Scotland, 2005-2014: a retrospective, population-based, observational study by Shaw, Martin et al.
D
ow
nloaded
from
https://journals.lw
w
.com
/ccejournalby
B
hD
M
f5eP
H
K
av1zE
oum
1tQ
fN
4a+kJLhE
ZgbsIH
o4X
M
i0hC
yw
C
X
1A
W
nY
Q
p/IlQ
rH
D
3kFt6O
S
S
8/9JjyH
/zH
3TvO
yH
xbo4FFY
rxIfA
88/D
cG
04M
w
36M
nA
sA
bg==
on
06/08/2020
Downloadedfromhttps://journals.lww.com/ccejournalbyBhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3kFt6OSS8/9JjyH/zH3TvOyHxbo4FFYrxIfA88/DcG04Mw36MnAsAbg==on06/08/2020
Critical Care Explorations www.ccejournal.org 1
Critical Care 
Explorations
Crit Care Expl 2020; 2:e0102
DOI: 10.1097/CCE.0000000000000102
1NHS Greater Glasgow and Clyde, Glasgow, Scotland, United Kingdom.
2Department of Internal Medicine, Division of Pulmonary & Critical Care, 
University of Michigan, Ann Arbor, MI.
3School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, 
Scotland, United Kingdom.
4Department of Critical Care Medicine, Faculty of Medicine and Dentistry and 
School of Public Health, University of Alberta, Edmonton, AB, Canada.
5The Alfred Hospital and the Australian and New Zealand Intensive Care 
Society (ANZICS) Centre for Outcome and Resource Evaluation (CORE), 
Melbourne, VIC, Australia.
6Austin Health and the Australian and New Zealand Intensive Care Research 
Centre (ANZIC-RC), Melbourne, VIC, Australia.
7Center for Clinical Management Research, VA Ann Arbor Healthcare System, 
Ann Arbor, MI.
Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. 
on behalf of the Society of Critical Care Medicine. This is an open-access 
article distributed under the terms of the Creative Commons Attribution-Non 
Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permis-
sible to download and share the work provided it is properly cited. The work 
cannot be changed in any way or used commercially without permission from 
the journal.
Observational Study
Timing of Onset, Burden, and Postdischarge 
Mortality of Persistent Critical Illness in 
Scotland, 2005–2014: A Retrospective, 
Population-Based, Observational Study
Martin Shaw, PhD, MSci1; Elizabeth M. Viglianti, MD, MPH, MSc2;  
Joanne McPeake, PhD, MSc, BN (Hons)1,3; Sean M. Bagshaw, MD, MSc, FRCPC3,4;  
David Pilcher, MBBS, MRCP(UK), FRACP, FCICM5;  
Rinaldo Bellomo, AO, MBBS, MD, FRACP, FCICM, FAHMS6;  
Theodore J. Iwashyna, MD, PhD, FCCM2,7; Tara Quasim, MD, MPH, MBChB1,3
Objectives: We aimed to understand the prevalence, timing of onset, 
resource use, and long-term outcomes of patients who developed 
persistent critical illness in a national dataset.
Design: Retrospective cohort. Using a physiologic risk adjustment 
model from ICU admission, we examined the relative ability of acute 
(related to reason for ICU presentation) and antecedent (demograph-
ics, comorbidities) characteristics to discriminate hospital mortality 
models. Persistent critical illness was defined as the point during an 
ICU stay when, at the population-level, patients’ acute diagnoses and 
physiologic disturbance are no longer more accurate at discriminat-
ing who survives than are baseline demographics and comorbidity. 
We examined the change across ICU stay in the relative discrimi-
nation of those characteristics, and short-term (in-hospital and 30 
d after admission) and medium-term (90 d after admission) survival. 
Finally, we analyzed the changes in the population definition of persis-
tent critical illness over time.
Setting: Patients admitted as level 3 to Scottish ICUs between 2005 
and 2014.
Patients: Seventy-two–thousand two-hundred fifty-three adult level 3 
ICU admissions in 23 ICUs across Scotland.
Interventions: None.
Measurements and Main Results: The onset of persistent critical ill-
ness, occurs at an average of 5.0 days (95% CI, 3.9–6.4 d) across 
this dataset. The crossing point increased across the decade, by an 
average of 0.36 days (95% CI, 0.22–0.50 d) per year. In this data-
set, 24,425 (33.8%) remained in the ICU long enough to meet this 
greater than 5-day definition of persistent critical illness. The care of 
such patients involved 72.3% ICU days used by any level 3 patient; 
46.5% of all Scottish ICU bed-days were after day 5. Although rates 
of 30 days after admission survival rose dramatically during the 
decade under study, these rates were similar for those with shorter or 
longer ICU stays, as were the rates of 90-day survival among those 
who survived at least 30 days.
Conclusions: Persistent critical illness occurred in one in three ICU 
patients in Scotland. These minority of patients accounted for dispro-
portionate hospital resources but did not have worse 30- or 90-day 
postadmission survival.
Key Words: chronic critical illness; cohort study; persistent critical 
illness; postdischarge mortality; prolonged mechanical ventilation
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One reason why patient might fail to either promptly recover or quickly die of critical illness has been termed persistent critical illness (PerCI)—the development of 
cascading new organ failures that render the ICU patient’s original 
reason for requiring critical care (1–4) less prognostically impor-
tant. It has been hypothesized that the onset of PerCI, at a popula-
tion-level, can be identified as the point during an ICU stay when 
patients’ acute diagnoses and physiologic disturbance on ICU pre-
sentation are no longer more accurate at discriminating who will 
live from who will die than are patients’ baseline demographics 
and comorbidity (5, 6).
Using this definition, the population-onset of critical illness 
was found to occur after ICU day 10 in Australia and New Zealand 
during 2000–2014 and after ICU day 9 in Alberta, Canada, during 
2012–2014 (5, 6). Such patients who become persistently critically 
ill (5% in Australia and New Zealand and 16% Alberta meet this 
population-level definition) accounted for large numbers of ICU 
bed-days (33% and 54%, respectively).
The generalizability of these findings to other health systems 
is unclear. Australia, New Zealand, and Alberta are considered to 
have relatively high numbers of critical care beds relative to both 
population and other hospital beds. In contrast, many systems 
operate with fewer critical care beds, or with different organiz-
ing principles. The United Kingdom is often considered a system 
with fewer critical care beds and uses a level 2 (1:2 nurse/patient 
ratio) and level 3 (1:1 nurse/patient ratio) distinction which is less 
common in Australia, New Zealand, and Canada. The prevalence, 
timing of onset, resource use, and outcomes of PerCI across such 
a system are not yet known.
Therefore, we examined 10 years of prospectively collected 
data in Scotland (Scottish Intensive Care Society Audit Group 
[SICSAG] database). We used a complete, nationally linked data 
set from 2005 to 2014 across all 23 public ICUs, who input data 
on each individual admission into this database. We closely rep-
licated methods used in Australia, New Zealand, and Alberta to 
allow comparability, while also providing, for the first time, infor-
mation on change in the population-onset of PerCI over time, and 
post-ICU survival.
MATERIALS AND METHODS
All data were anonymized and part of routinely collected data 
across Scotland. As a result, ethics approval was sought and 
deemed not necessary. Approvals were obtained from SICSAG 
as well as the Scottish National Data Governance Body (Privacy 
Board Committee, Information Services Division).
Variables
The SICSAG dataset included prospective entry of physiologic 
variables including admitting specialty, age, gender, Acute 
Physiology and Chronic Health Evaluation (APACHE) II scor-
ing, length of stay (LOS), length of mechanical ventilation, car-
diovascular support, renal replacement therapy, and ICU survival 
and hospital survival. This dataset was then linked to the Scottish 
death records dataset.
All patients over the age of 16 years and who were level 3 
patients were included in the analysis. Level 3 patients, per the 
U.K. Intensive Care Society’s definition, require multiple organ 
support or invasive respiratory support. Within the U.K. context, 
level 3 patients require a critical care environment in the acute 
hospital setting. Within this dataset, all patients had at least 1 day 
of level 3 care, although not necessarily their first ICU day. Each 
distinct admission to the ICU was included in the data as we are 
not able to distinguish “readmissions” from first visits; note that 
this is different from prior analyses, which have excluded patients 
with previous ICU stays from the denominator at risk for develop-
ing PerCI (4–7).
Demographic data, diagnoses, and risk-adjustment data were 
obtained from the SICSAG database. Additional information 
about the organization of Scottish critical care services is available 
at http://www.sicsag.scot.nhs.uk.
Statistical Analysis
All statistical analyses were carried out in R Version 3.5.2 (R 
Foundation for Statistical Computing, Vienna, Austria), using 
Multivariate Adaptive Regression Splines (MARS) models from 
the Earth R package Version 4.7.0 (https://CRAN.R-project.org/
package=earth) and summary statistics from the Tangram R package 
Version 0.6.2 (https://CRAN.R-project.org/package=tangram) (8).
For simple comparison statistics, Kruskal-Wallis tests were 
applied to all numeric comparisons and Pearson chi-square tests 
to all categorical covariates with a p value of 0.05 considered 
significant.
Conceptually, the goal of the primary analyses was to identify 
the population-level crossing point at which acute characteristics 
no longer better discriminate who will live from who will die than 
do antecedent characteristics. In order to do so, we used an objec-
tive, automated approach to build the best possible risk-of-hospi-
tal-death prediction model using each of the two sets of variables 
separately. Then we ran the two separate models on the patients 
still in the ICU at a given LOS and compared their discrimination 
in those patients as the area under the receiver operating char-
acteristic curve (AUROC, which is equivalent to the C-statistic).
More specifically, initially, a full logistic MARS model was built 
combining both the acute and antecedent covariates, enabling 
a complete risk of “hospital” mortality to be calculated across 
all patients. Note that the MARS model automatically allowed 
nonlinearities in continuous variables. All included variables are 
shown in Appendix A (Supplemental Digital Content 1, http://
links.lww.com/CCX/A159); the exact nonlinear weightings are 
calculated through this process internally. The full dataset was cat-
egorized into hospital risk greater than 66% (high), between 33% 
and 66% (moderate), and less than 33% (low) groups, as had been 
done in the past, and displays in-ICU mortality.
For the primary analyses, we focused on “hospital” mortal-
ity, since that is less susceptible to variation driven by ICU bed 
pressures. The main data set was then split into 28 reduced sets 
based on ICU LOS, each split containing only those patients still 
in the ICU on or after the given LOS. A 100-fold stratified cross-
validation process was then applied to each of these 28 LOS splits 
creating 100 randomly chosen datasets for each LOS split. This 
cross-validation process divided each of the 100 created datasets 
into a set of two thirds, one third, training and validation datasets 
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using a stratified approach based on hospital mortality. This ran-
domly chose patients to be in the training and validation sets such 
that the overall proportion of hospital mortality remained equal to 
the proportion in the original complete LOS dataset. The cross-val-
idation processes also ensured that a patient was only included in 
a single validation cohort across any of the 100 random divisions.
To maximize the likelihood of finding a good set of models, 
imputation was then applied to each of the new training and vali-
dation datasets in line with that in previous applications of this 
technical process (6). All continuous acute physiologic predictors’ 
single imputation with normal value substitution was performed. 
For patients with missing ages, the median cohort age was used. 
Finally, for all categorical variables, the missing values were made 
explicit by adding in a new category, “Missing,” to account for this. 
The imputation process was applied to each of the cross-validation 
splits to offset any random bias introduced by the imputation pro-
cedures and the cross-validation sampling process.
A logistic MARS model with backward step pruning and inter-
actions was then fit to each of the imputed training datasets. This 
step removes nonsignificant variables using Akaike information 
criterion. These models are essentially a logistic regression with 
stepwise parameter selection allowing for nonlinear trends in the 
continuous covariates via hinge function splines. Allowing for 
nonlinearity within the modeling process enables a better fit due 
to the complex nature of most physiologic processes. Day 1 physi-
ologic and chronic health scores were used in all analyses.
A number of assessment metrics (accuracy, agreement, and 
discrimination) for each of the model fits were then produced. For 
each of these statistics, the median as well as the upper and lower 
95th percentiles were then calculated across each of the 100-folds 
to produce a summary of the statistic. The summaries of the dis-
crimination, measured by the AUROC, were then extracted and 
plotted per day in the given LOS for each acute or chronic model 
fit. As a sensitivity analysis, this was replicated using only the acute 
and antecedent risk scores from the day 1 cohort.
The crossing point as well as upper and lower confidence bounds 
for the crossing point of the acute and antecedent models was solved 
using a minimization routine (9). This process resulted in two risk 
models of hospital mortality: one utilizing antecedent covariate 
and one with the acute covariates. We define the onset of PerCI—
consistent with past publications—as the point at which the acute 
model is no longer better discriminates than the antecedent model.
The yearly crossing point was calculated using the same method 
as above, with stratification of the dataset by year.
Mortality at 30 and 90 days after admission was also examined 
among hospital survivors. Of note, we also examined two previ-
ously published definitions of PerCI in this analysis (day 8 and 10), 
in addition to the definition established within Scotland (5, 6).
RESULTS
There were 72,253 adult level 3 ICU admissions in 23 ICUs in 
Scotland during 2005–2014. Overall, 18,067 died (25.0%) as an 
inpatient. Thirty-day survival (counting from ICU admission) 
increased dramatically during the time under study (65.1% in 
2005 vs 80.9% in 2013). Level 3 patients’ median age was 61 (inter-
quartile range [IQR], 47–71), and median APACHE II score was 
18 (IQR, 11–24). The most common specific diagnoses were bac-
terial pneumonia, cardiac or respiratory arrest, gastrointestinal 
perforation or rupture, and self-inflicted overdose (Table 1).
Trajectories of Risk of Death
When patients were divided into higher (> 66% risk of death), 
medium (34–66%), and lower (≤ 33%) risk according to the pre-
dicted hospital mortality from the initial combined MARS model, 
there were (as expected) substantial differences in early mortality 
among the groups. (Fig. 1; note these initial descriptive data show 
ICU mortality). However, among those still in the ICU, those ini-
tially in the higher risk group rapidly became less likely to die with 
each additional day in the ICU—declining from 73.9% in-ICU 
mortality among all 7,013 higher risk patients to 43.6% in-ICU 
mortality by day 5 (of 1,963 high-risk patients still in the ICU at 
day 5, 856 died thereafter) and 38.6% by day 10 (of 1,001 initially 
higher risk patients still in the ICU on day 10, 386 died thereaf-
ter). Indeed, among those who were in the ICU from this initially 
higher risk group, in-ICU mortality declined to 35% by day 28 (of 
171 still in the ICU). In contrast, in the large lower-risk popula-
tion of 51,698 patients admitted, ICU mortality was 8%, but rose 
to 13.3% still in ICU on day 10 (of 8,903 initially low-risk patients 
still in the ICU on day 10, 1,180 died thereafter), plateauing at that 
level thereafter. Among those who died in the hospital, the median 
time to death was 3 days (IQR, 1–11 d), decreasing from 4 days 
(IQR, 1–12 d) in 2005 to 3.5 days (IQR, 1–10 d) in 2013.
Population-Level Onset of PerCI
On ICU presentation, characteristics of acute physiology were 
substantially more effective than were antecedent characteristics 
at discriminating patients who would and would not die in the 
hospital. However, the discriminative ability of day 1 acute char-
acteristics fell rapidly, and by ICU day 5.0 (95% CI, 3.9–6.4 d) was 
not superior to that of antecedent characteristics. (Fig. 2; note that 
these primary analytic data use in-hospital mortality) When this 
analysis was replicated in a sensitivity analysis using the only the 
acute and antecedent risk weights from day 1, the cross-over was 
at day 4.6 (95% CI, 3.9–5.4 d).
However, there was evidence of substantial change over time in 
the cross-over (Fig. 3). In 2005 data analyzed alone, the cross-over 
point was day 5.3 (95% CI, 2.6–6.0 d). In contrast, in 2013 data 
analyzed alone, the estimated cross-over point was at day 6.9 (95% 
CI, 4.1–10.0 d). Smoothing over all years, there was evidence that 
the cross-over point defining the population prevalence of PerCI 
became progressively delayed across this decade, increasing on 
average by 0.36 days (95% CI, 0.22–0.50 d) per year during the 
period under study.
Of all level 3 ICU patients, 24,425 (33.8%) remained in the 
ICU long enough to meet the time-averaged 5-day definition of 
PerCI—that is, they remained in ICU for greater than 5 days. The 
care of such patients involved 342,202 of the 473,145 (72.3%) ICU 
days used by any level 3 patient during that decade. Indeed, 46.5% 
of all Scottish ICU bed occupancies are used by patients after 5 
days. Similar high-levels of use were present for other population-
level cutoffs. Of all level 3 ICU patients, 17,698 remained in the 
ICU for 8 or more days, using 298,937 (63.2%) ICU days; 32.6% of 
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TABLE 1. Characteristics of the Cohort
Characteristic Overall (n = 72,253) Survived (n = 54,186) Died (n = 18,067)
Age 61 (47–71) 59 (44–70) 66 (55–75)
Male sex 41,898 (58.0) 31,779 (58.7) 10,119 (56.0)
APACHE II score (n = 72,247) 18 (11–24) 16 (10–21) 24 (17–30)
ICU LOS 4 (2–7) 4 (2–7) 3 (2–8)
Hospital LOS 11 (5–24) 14 (7–28) 4 (2–12)
Admitting specialty n = 72,214 n = 54,161 n = 18,053
 General medicine 20,842 (28.9) 14,539 (26.8) 6,303 (34.9)
 General surgery 18,072 (25.0) 13,407 (24.8) 4,665 (25.8)
 Other 10,998 (15.2) 8,761 (16.2) 2,237 (12.4)
 Cardiothoracic 6,541 (9.1) 6,182 (11.4) 359 (2.0)
 Neurosurgery 4,272 (5.9) 3,302 (6.1) 970 (5.4)
 Vascular surgery 2,545 (3.5) 1,885 (3.5) 660 (3.7)
 Orthopedics 2,468 (3.4) 1,984 (3.7) 484 (2.7)
 Gastroenterology 2,430 (3.4) 1,471 (2.7) 959 (5.3)
 Cardiology 2,297 (3.2) 1,412 (2.6) 885 (4.9)
 Respiratory medicine 1,749 (2.4) 1,218 (2.3) 531 (2.9)
APACHE III diagnosis
 Other 42,241 (58.5) 31,637 (58.4) 10,604 (58.7)
 Bacterial pneumonia 7,028 (9.7) 4,587 (8.5) 2,441 (13.5)
 Post cardiac ± respiratory arrest 4,124 (5.7) 1,919 (3.5) 2,205 (12.2)
 Gastrointestinal perforation/rupture 3,367 (4.7) 2,488 (4.6) 879 (4.9)
 Self-inflicted overdose 3,292 (4.6) 3,214 (5.9) 78 (0.43)
 Coronary artery bypass grafting 2,653 (3.7) 2,616 (4.8) 37 (0.2)
 Septic shock-unknown origin 2,339 (3.2) 1,331 (2.5) 1,008 (5.6)
 Seizures 2,197 (3.0) 1,984 (3.7) 213 (1.2)
 Valvular repair/replacement 1,787 (2.5) 1,748 (3.2) 39 (0.2)
 Gastrointestinal obstruction (any cause) 1,747 (2.4) 1,382 (2.6) 365 (2.0)
 Gastrointestinal neoplasm (not perforation/obstruction) 1,478 (2.0) 1,280 (2.4) 198 (1.1)
Comorbidities
 Severe cardiovascular disease 2,155 (3.0) 1,294 (2.4) 861 (4.8)
 Severe respiratory disease 3,357 (4.6) 2,037 (3.8) 1,320 (7.3)
 Biopsy proven cirrhosis 1,402 (1.9) 920 (1.7) 482 (2.7)
 Portal hypertension 3,167 (4.4) 1,984 (3.7) 1,183 (6.5)
 Hepatic encephalopathy 1,643 (2.3) 865 (1.6) 778 (4.3)
 Acute leukemia 251 (0.3) 121 (0.2) 130 (0.7)
 Chronic leukemia 334 (0.5) 202 (0.4) 132 (0.7)
 Metastatic cancer 2,159 (3.0) 1,479 (2.7) 680 (3.8)
 Lymphoma 737 (1.0) 415 (0.8) 322 (1.8)
 AIDS 169 (0.2) 119 (0.2) 50 (0.3)
 Immunosuppression 3,097 (4.3) 1,992 (3.7) 1,105 (6.1)
 Chronic renal replacement therapy 1,274 (1.8) 900 (1.7) 374 (2.1)
APACHE = Acute Physiology and Chronic Health Evaluation, LOS = length of stay.
Observational Study
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Figure 1. ICU mortality for patients. Unadjusted ICU mortality, stratified by patients’ overall probability of death at admission. Probability of death is based on 
their ICU admission total predicted risk of death from a logistic regression including both the acute and antecedent risk scores. The numbers of patients between 
groups are unbalanced as they were chosen for illustrative purposes to span clinically relevant ranges of patients and comparability with past work.
Figure 2. Predictiveness of acute (ICU presentation) and antecedent characteristics for hospital mortality. Shaded areas are 95% CIs. Appendix 1 (Supplemental 
Digital Content 1, http://links.lww.com/CCX/A159) contains all characteristics. ROC AUC = area under the receiver operating characteristic curve.
Shaw et al
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all Scottish ICU bed occupancies are used by patients who reach 
8-day landmark. Of all level 3 ICU patients, 13,423 remained in 
the ICU for 10 or more days, using 262,763 (55.5%) ICU days; 
27.2% of all Scottish ICU bed occupancies are used by patients 
who reached 10 days of admission.
Patients who went on to develop PerCI in Scotland had several 
differences than those who did not (Appendix B, Supplemental 
Digital Content 2, http://links.lww.com/CCX/A160). Patients who 
went on to develop PerCI, defined by an ICU LOS of greater than 
5 days, were more acutely physiologically deranged on ICU pre-
sentation (APACHE II score of 20 vs 16; p < 0.01), and somewhat 
more likely to be admitted with general medical or surgical diag-
noses. Although statistically significant, there were few clinically 
meaningful differences in the rates of APACHE II severe comor-
bidities. Similar results were obtained using an 8- or 10-day cut-
off. Despite the relatively modest differences between the groups 
on any given characteristic, the best-fitting MARS model had an 
accuracy of 74.2% (95% CI, 73.5–74.7%) and an area under the 
curve (AUC) discrimination of 0.79 (95% CI, 0.78–0.8) at day 5, 
79.7% (95% CI, 79.2–80.1%) and an AUC discrimination of 0.79 
(95% CI, 0.78–0.8) at day 8, and 83.5% (95% CI, 83.2–83.9%) and 
an AUC discrimination of 0.78 (95% CI, 0.77–0.79) at day 10.
Subsequent Outcomes
In Scotland, there were no clinically meaningful differences in 
short-term or medium-term rates of survival between those who 
did and did not develop PerCI. For example, of the 47,828 patients 
who were in ICU for less than equal to 5 days, 35,892 survived 
(75%) to hospital discharge whilst 18,294 (74.9%) of the longer 
staying patients survived the hospital. The rates of 30 days after 
ICU admission survival were likewise similar (35,461/47,828 
[74.1%] vs 19,010/24,425 [77.8%]), as were the rates of 90-day sur-
vival after ICU admission (34,327/47,828 [71.8%] vs 17,711/24,425 
[72.5%]). Similar results were true for 30-day survival (counting 
from ICU admission) using the cutoff of day 8 (74.5% vs 78.5%) 
and day 10 (74.6% vs 79.4%), and this lack of difference in sur-
vival as a function of ICU LOS was true when analyzing data over 
time as well. In contrast, there was marked variation over time in 
30-day survival among those who stayed at least 5 days (62.5% in 
2005 vs 80.1% in 2013), 8 days (62.7% in 2005 vs 80.9% in 2013), 
and 10 days (74% in 2005 vs 81.6% in 2013).
DISCUSSION
PerCI has been defined, at the population level as the point dur-
ing an ICU stay when patients’ acute diagnoses and physiologic 
disturbance on ICU presentation are no longer more accurate at 
discriminating who will live from who will die than are patients’ 
baseline demographics and comorbidity. PerCI is quite com-
mon in Scotland. The onset of PerCI is earlier in Scotland than 
in Australia, New Zealand, and Alberta. The timepoint on onset 
changed in Scotland contemporaneous with a major expansion 
of ICU capacity and investment in the National Health Service. 
Yet by either the Scottish population transition point (either after 
ICU day 5, or the more recent transition point of day 8) or the 
Australian/New Zealand population transition point (after ICU 
day 10), caring for patients with PerCI accounts for one-quarter to 
nearly one-half of the day-to-day work of Scottish ICUs. Despite 
Figure 3. Estimated Crossing points (d) stratified by year.
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the quite high short-term mortality of these persistently critically 
ill patients (25%), their subsequent 30- and 90-day mortality if 
discharged alive was high but by no means uniformly fatal.
These data extend the emerging story of PerCI in several ways. 
First, they replicate the core finding of past work that there is a point 
in the ICU stay, for which prognostic relevance of the driver for ICU 
admission diminishes—and that this transition occurs at a clinically 
meaningful timepoint and happens commonly (4–7). The bedside 
clinical implication of this finding is not that it should be used to 
prognosticate for any given patient; instead, it has been argued, the 
clinical implication of this finding may be that there are groups 
of patients are at increased risk of iatrogenesis, and that iatrogen-
esis may be caused by decision-making anchoring on the patient’s 
diagnosis and prognosis as defined at ICU admission, rather than 
updating to reflect the patients’ dynamically changing status (10). 
These data show a relatively rapid increasing statistical discrimina-
tory capacity of admission characteristics in comparison to other 
populations in which this phenomenon has been examined (7, 11).
Second, these results show an important and previously unde-
scribed change in the population cross-over defining critical ill-
ness in the context of a rapidly changing  healthcare system. It 
has been unclear to what extent PerCI represents an unfolding 
of pathology in patients over time, and to what extent its onset 
is modifiable by changes in care. These data suggest—but do not 
prove—that the onset of PerCI may be modified by care practices 
and/or the organization of critical care services. There is an urgent 
need to understand to what specific practices drive this change, 
and whether PerCI is more common at higher quality hospitals 
(representing an unfortunate “legacy of critical illness”) or instead 
represent another measure of imperfectly delivered care (12).
At the same time, artifactual differences resulting from differ-
ences in data cannot be fully excluded. For example, all population-
based analyses use timing of ICU admission as an approximation 
for timing of onset of critical illness and thereby onset of time 
at risk for developing PerCI. If Scottish patients tend to present 
to ICU later in their illness (despite adjustment for APACHE II 
score), and access to ICUs has changed during the time period 
under study, this would create the appearance of earlier onset via a 
mechanism that is the inverse of lead-time bias. Similarly, limita-
tions of this dataset prevent us from excluding patients with pre-
vious critical illness in the same or prior hospitalizations, which 
would have similar impacts, or with preexisting neuromuscular 
disease. Finally, it may be that patients who will die within the 
hospital die more quickly in some systems than others (13, 14); yet 
we find a median time to death of 3 days (IQR, 1–11 d) compared 
with 2.3 days (IQR, 0.9–5.7 d) in Australia and New Zealand (R. 
Bellomo, unpublished data, 2020) or 8.5 days (IQR, 2.0–25 d) in 
Alberta (S. Bagshaw, unpublished data, 2020).
A third contribution of these Scottish data is to, for the first 
time, measure the postdischarge mortality of patients with PerCI 
as defined here. Australia/New Zealand data were unable to mea-
sure this. It is has been proposed that patients with PerCI might 
be at high risk for futile care; if care for the persistently critically 
ill were futile, we would expect near uniform death in the weeks 
to months after hospital discharge. Instead, while mortality is 
certainly high and ongoing, the majority of patients who survive 
hospital discharge are still alive 90 days after admission (3). The 
contribution to such later postdischarge mortality attributable to 
PerCI needs to be defined in future work; it was found to be quite 
high for sepsis, but rather more modest for acute hypoxemic respi-
ratory failure (15, 16).
These data have limitations beyond those mentioned above. 
Most importantly, specific care practices that mediate these out-
comes have not been identified in this initial work. Candidate care 
practices have been identified by a recent systematic review and 
will require novel data collection to measure (17). Second, we rep-
licated past work in operationalizing the measurement of onset of 
critical illness (our target concept) as the timing of ICU admission, 
and the duration of critical illness (our target concept) as the time 
in level 2 or level 3 ICU care. To the extent that a hardy reluctance 
to seek care, widely available rapid response teams, or differences 
between Scottish and Australian/New Zealand/Alberta defini-
tion of ICU exist, those may introduce interpretive challenges. 
Third, PerCI is one concept in the family of concepts that are 
lumped together under the label of chronic critical illness; mea-
suring other concepts may produce other results (2). Fourth, we 
have not determined whether the transition from acute to PerCI 
can be determined at an individual-patient level, a task for which 
machine learning approaches might be particularly suitable.
CONCLUSIONS
In conclusion, patients cared for in 23 Scottish ICUs over a decade 
often manifested the onset of PerCI when defined on a population 
basis using methods comparable to past work. These data showed 
more rapid onset of patients with PerCI, that the timing of onset 
at the population-level changed across the decade understudy, 
and that patients after the onset account for a substantial amount 
of the work of these ICUs. While inpatient mortality was high, 
postdischarge mortality was not uniformly terminal. Mechanistic 
insights and new care practices that may drive better outcomes for 
these patients are urgently needed and could free up substantial 
ICU resources for other patients.
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